Expression and inhibitory effects of p53‑upregulated modulator of apoptosis in gallbladder carcinoma

Liu,Zhide; Yan,Cheng; Xiao,Yangyan; Zhang,Weichang; Wang,Li; Li,Qinglong; Cai,Wenwu

doi:10.3892/ol.2021.12495

Expression and inhibitory effects of p53‑upregulated modulator of apoptosis in gallbladder carcinoma

Authors:
- Zhide Liu
- Cheng Yan
- Yangyan Xiao
- Weichang Zhang
- Li Wang
- Qinglong Li
- Wenwu Cai
View Affiliations

Affiliations: Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China
Published online on: January 26, 2021 https://doi.org/10.3892/ol.2021.12495
Article Number: 234
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The p53‑upregulated modulator of apoptosis (PUMA) has been reported to be involved in various types of cancer. However, its potential biological role in gallbladder carcinoma (GBC) has not been fully elucidated. The present study aimed to determine the expression levels of PUMA and its biological effects on GBC. The mRNA and protein expression levels of PUMA in GBC tissues and cell lines were measured using reverse transcription‑quantitative PCR and western blotting, respectively. The effects of PUMA overexpression on cell viability, proliferation and invasive ability were determined in vitro using the MTT, colony formation and Transwell invasion assays, respectively. The apoptotic rates were detected using the Annexin V‑FITC apoptosis detection kit. Furthermore, follow‑up of patients with GBC was performed to identify the association between PUMA expression levels and GBC prognosis. The results of the present study demonstrated that the expression levels of PUMA were significantly lower in the GBC tissues and cell lines compared with those in adjacent normal gallbladder tissues and normal gallbladder cells, respectively. Further experiments indicated that overexpression of PUMA inhibited the viability, proliferation and invasive ability of GBC cells compared with those in the control‑transfected GBC cells. In addition, overexpression of PUMA significantly promoted apoptosis in GBC cells. Furthermore, overexpression of PUMA inhibited epithelial‑mesenchymal transition, and promoted Bax upregulation and Bcl‑2 downregulation compared with those in the control group. Low PUMA expression levels were associated with a short overall survival time in patients with GBC. In conclusions, PUMA may act as a tumor suppressor in GBC and may serve as a potential novel treatment target for human GBC.

View Figures

View References

1	Kanthan R, Senger JL, Ahmed S and Kanthan SC: Gallbladder Cancer in the 21st Century. J Oncol. 2015:9674722015. View Article : Google Scholar : PubMed/NCBI
2	Jiahong D, Jianming W and Jianping Z: Guidelines for diagnosis and treatment of gallbladder cancer (2015 edition). J Clin Hepatol. 32:411–419. 2015.
3	Kakaei F, Beheshtirouy S, Nejatollahi SM, Zarrintan S and Mafi MR: Surgical treatment of gallbladder carcinoma: A critical review. Updates Surg. 67:339–351. 2015. View Article : Google Scholar : PubMed/NCBI
4	Cziupka K, Partecke LI, Mirow L, Heidecke CD, Emde C, Hoffmann W, Siewert U, van den Berg N, von Bernstorff W and Stier A: Outcomes and prognostic factors in gallbladder cancer: A single-centre experience. Langenbecks Arch Surg. 397:899–907. 2012. View Article : Google Scholar : PubMed/NCBI
5	Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G and Nervi F: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar : PubMed/NCBI
6	Mekeel KL and Hemming AW: Surgical management of gallbladder carcinoma: A review. J Gastrointest Surg. 11:1188–1193. 2007. View Article : Google Scholar : PubMed/NCBI
7	Zhang LF, Hou CS, Xu Z, Guo LM, Ling XF, Wang LX and Xiu DR: Laparoscopic treatment for incidental gallbladder cancer: A retrospective 10 years study from a single institution. Zhonghua Wai Ke Za Zhi. 57:277–281. 2019.(In Chinese). PubMed/NCBI
8	Butte JM, Matsuo K, Gönen M, D'Angelica MI, Waugh E, Allen PJ, Fong Y, DeMatteo RP, Blumgart L, Endo I, et al: Gallbladder cancer: Differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg. 212:50–61. 2011. View Article : Google Scholar : PubMed/NCBI
9	Yu J: PUMA kills stem cells to stall cancer? Mol Cell Pharmacol. 1:112–118. 2009. View Article : Google Scholar : PubMed/NCBI
10	Yu J, Wang Z, Kinzler KW, Vogelstein B and Zhang L: PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA. 100:1931–1936. 2003. View Article : Google Scholar : PubMed/NCBI
11	He S, Ma X, Ye Y, Zhang M, Zhuang J, Song Y and Xia W: HEATR1 modulates cell survival in non-small cell lung cancer via activation of the p53/PUMA signaling pathway. Onco Targets Ther. 12:4001–4011. 2019. View Article : Google Scholar : PubMed/NCBI
12	Yee KS, Wilkinson S, James J, Ryan KM and Vousden KH: PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ. 16:1135–1145. 2009. View Article : Google Scholar : PubMed/NCBI
13	Sinicrope FA, Rego RL, Okumura K, Foster NR, O'Connell MJ, Sargent DJ and Windschitl HE: Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res. 14:5810–5818. 2008. View Article : Google Scholar : PubMed/NCBI
14	Diallo JS, Aldejmah A, Mouhim AF, Péant B, Fahmy MA, Koumakpayi IH, Sircar K, Bégin LR, Mes-Masson AM and Saad F: NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res. 13:7044–7052. 2007. View Article : Google Scholar : PubMed/NCBI
15	Nevin JE, Moran TJ, Kay S and King R: Carcinoma of the gallbladder: Staging, treatment, and prognosis. Cancer. 37:141–148. 1976. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Sharma A, Kumar A, Kumari N, Krishnani N and Rastogi N: Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients. Ecancermedicalscience. 11:7572017. View Article : Google Scholar : PubMed/NCBI
18	Kim YW, Huh SH, Park YK, Yoon TY, Lee SM and Hong SM: Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep. 8:1127–1132. 2001.PubMed/NCBI
19	Niizuma K, Endo H, Nito C, Myer DJ and Chan PH: Potential role of PUMA in delayed death of hippocampal CA1 neurons after transient global cerebral ischemia. Stroke. 40:618–625. 2009. View Article : Google Scholar : PubMed/NCBI
20	Sun YL, Jiang WQ, Luo QY, Yang DJ, Cai YC, Huang HQ and Sun J: A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway. BMC Cancer. 20:12019. View Article : Google Scholar : PubMed/NCBI
21	Letai A: Puma strikes Bax. J Cell Biol. 185:189–191. 2009. View Article : Google Scholar : PubMed/NCBI
22	Erlacher M, Labi V, Manzl C, Böck G, Tzankov A, Häcker G, Michalak E, Strasser A and Villunger A: Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med. 203:2939–2951. 2006. View Article : Google Scholar : PubMed/NCBI
23	Cai W, Li Q, Yang Z, Miao X, Wen Y, Huang S and Ouyang J: Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance. Clin Transl Oncol. 15:818–824. 2013. View Article : Google Scholar : PubMed/NCBI
24	Shu GS, Lv F, Yang ZL and Miao XY: Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances. Int J Clin Oncol. 18:641–650. 2013. View Article : Google Scholar : PubMed/NCBI
25	Wei D, Zhang X, Zou H, Wang L, Fu B, Wu X, Luo Z, Li X, Ge J, Li Y, et al: WW domain containing oxidoreductase induces apoptosis in gallbladder-derived malignant cell by upregulating expression of P73 and PUMA. Tumour Biol. 35:1539–1550. 2014. View Article : Google Scholar : PubMed/NCBI
26	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and desease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
27	Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ, Zhou SL, Zhao YM, Xiao YS, Sun QM, Ding ZB and Fan J: Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int J Oncol. 46:587–596. 2015. View Article : Google Scholar : PubMed/NCBI
28	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
29	Babu PP, Suzuki G, Ono Y and Yoshida Y: Attenuation of ischemia and/or reperfusion injury during myocardial infarction using mild hypothermia in rats: An immunohistochemical study of bcl-2, bax, Bak and TUNEL. Pathol Int. 54:896–903. 2004. View Article : Google Scholar : PubMed/NCBI
30	Duan XX, Ou JS, Li Y, Su JJ, Ou C, Yang C, Yue HF and Ban KC: Dynamic expression of apoptosis related genes during development of laboratory hepatocellular carcinoma and its relation to apoptosis. World J Gastroenterol. 11:4740–4744. 2005. View Article : Google Scholar : PubMed/NCBI
31	Martin LJ: Neuronal cell death in nervous system development, disease, and injury (Review). Int J Mol Med. 7:455–478. 2001.PubMed/NCBI
32	Cecconi F, Alvarez-Bolado G, Meyer BI, Roth KA and Gruss P: Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell. 94:727–737. 1998. View Article : Google Scholar : PubMed/NCBI
33	McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM and Campbell ML: Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:6940–6944. 1992.PubMed/NCBI
34	Roos A, Sato T, Maier H, van Kooten C and Daha MR: Induction of renal cell apoptosis by antibodies and compiement. Exp Nephrol. 9:65–70. 2001. View Article : Google Scholar : PubMed/NCBI
35	Fan ZC, Yan J, Liu GD, Tan XY, Weng XF, Wu WZ, Zhou J and Wei XB: Real-time monitoring of rare circulating hepatocelluar carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis. Cancer Res. 72:2683–2691. 2012. View Article : Google Scholar : PubMed/NCBI
36	Yan J, Fan Z, Wu X, Xu M, Jiang J, Tan C, Wu W, Wei X and Zhou J: Circulating tumor cells are correlated with disease progression and treatment response in an orthotopic hepatocellular carcinoma model. Cytometry A. 87:1020–1028. 2015. View Article : Google Scholar : PubMed/NCBI